NCT04410198 - Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants | Biotech Hunter

Enrollment

203

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

October 11, 2021

Conditions

Anemia Associated With End Stage Renal Disease (ESRD)

Interventions

DRUG

Roxadustat

Roxadustat will be administered per dose and schedule specified in the arm description.

Trial Locations (9)

Investigational Site, Tupelo

Investigational Site, Kalamazoo

Investigational Site, Saint Ann

Investigational Site, Baton Rouge

Investigational Site, Sugar Land

Investigational Site, Englewood

Investigational Site, Caldwell

Investigational Site, St. George

Investigational Site, Las Vegas